Anticholinergic Cognitive Burden Scale IDs Adverse Outcomes

This article originally appeared here.
Share this content:
Anticholinergic Cognitive Burden Scale IDs Adverse Outcomes
Anticholinergic Cognitive Burden Scale IDs Adverse Outcomes

MONDAY, Nov. 27, 2017 (HealthDay News) -- For older adults, the Anticholinergic Cognitive Burden Scale (ACB) shows good dose-response relationships between anticholinergic burden and adverse outcomes, according to a study published in the November/December issue of the Annals of Family Medicine.

Wen Han Hsu, from the National Taiwan University in Taipei, and colleagues retrieved data on monthly anticholinergic drug use measured by the Anticholinergic Risk Scale (ARS), the ACB, and the Drug Burden Index - Anticholinergic component (DBI-Ach) for 116,043 people aged 65 years and older. The authors examined the correlation between anticholinergic burden and adverse outcomes during a 10-year follow-up.

The researchers found that the ACB showed the strongest and most consistent dose-response relationships with risks of all four adverse outcomes compared with ARS and DBI-Ach, especially among those aged 65 to 84 years. For adults aged 65 to 74 years, an increase of ACB score from 1 to 4 or greater correlated with increased adjusted odds ratios for emergency department visits (1.41 to 2.25), all-cause hospitalizations (1.32 to 1.92), fracture-specific hospitalizations (1.10 to 1.71), and incident dementia (3.13 to 10.01).

"For primary care and geriatrics clinicians, the ACB may be a helpful tool for identifying high-risk populations for interventions," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »